Xtant Medical Announces Completion Of Secondary Private Sale Of 73.1M Shares By Funds Affiliated With OrbiMed Advisors; Co. Also Says Expects Prelim. Q1 Revenue $32.8M-$33.1M, Representing 18-19% Growth YoY Driven By Orthobiologics And Licensing Revenue
Author: Benzinga Newsdesk | April 16, 2025 08:13am